GAITHERSBURG, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with a new fundamental institutional investor for the purchase and sale of 17,045,454 shares of its common stock (or pre-funded warrants in lieu thereof) pursuant to a registered direct offering. The g ...

Core Viewpoint - Solid Power, Inc. has entered into a securities purchase agreement with a sector-focused institutional investor for the sale of common stock and warrants, indicating a strategic move to raise capital for its solid-state battery technology development [1] Group 1: Securities Purchase Agreement - The agreement involves the purchase and sale of 17,000,000 shares of common stock [1] - It includes pre-funded warrants to purchase an aggregate of 5,807,018 shares of common stock [1] - Additionally, the agreement features common warrants to purchase up to an aggregate of 45,614,036 shares of common stock [1]

Core Viewpoint - Altimmune, Inc. has entered into a securities purchase agreement for the sale of 17,045,454 shares of common stock, expected to generate approximately $75 million in gross proceeds, to fund its Phase 3 trial for pemvidutide and for general corporate purposes [1][2]. Group 1: Offering Details - The offering involves 17,045,454 shares of common stock or pre-funded warrants, with gross proceeds anticipated to be around $75 million before expenses [1]. - The offering is expected to close on or about January 29, 2026, pending customary closing conditions [1]. - Titan Partners is acting as the sole placement agent for this offering [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to prepare for the upcoming Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH), along with working capital and general corporate purposes [2]. - Pemvidutide is a dual agonist targeting glucagon and GLP-1 receptors, showing potential as a differentiated therapy for MASH, supported by recent Phase 2b data and Breakthrough Therapy Designation from the U.S. FDA [2]. Group 3: Company Overview - Altimmune is a late clinical-stage biopharmaceutical company focused on therapies for serious liver diseases, with pemvidutide as its lead candidate [6]. - The company aims to deliver significant patient impact and long-term shareholder value through its innovative therapies [2].

Arbe Robotics (ARBE) priced an underwritten offering of 11,500,000 ordinary shares at a purchase price of $1.40 per share. Arbe estimates the gross proceeds from this offering to be approximately $16.1M before deducting underwriting discounts and commissions and other offering expenses. Arbe expects to grant the underwriters a 30-day option to purchase up to an additional 1,725,000 ordinary shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close o ...

New York, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a registered direct offering (the “Offering”) of approximately $10 million for its client China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) (the “Company” or “China SXT”), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Tr ...

TAIZHOU, China, Jan. 09, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the “Company”), today announced that it has entered into a definitive agreement with a single investor for the purchase and sale of an aggregate of 66,666,666 Class A ordinary shares of the company, no par value per share (the “Shares”) (or pre-funded warrants in lieu thereof), at a purchase price of $0.15 per share in a registered direct offering. The purchase price for each pre-funded warrant is identical to t ...

Core Viewpoint - STAK Inc. has successfully closed a registered direct offering of 6,000,000 units at a price of US$0.38 per unit, raising approximately US$2.3 million in gross proceeds [1]. Group 1: Offering Details - Each unit consists of one Class A ordinary share and one and one-half warrants, with a total of 6,000,000 Class A ordinary shares issued [2]. - Up to 9,000,000 additional Class A ordinary shares may be issued upon the exercise of the warrants, which have a three-year term and an initial exercise price of US$0.46 per share [2]. - The company received net proceeds of approximately US$2.2 million after deducting offering expenses, which will be used for research and development, working capital, and other general corporate purposes [3]. Group 2: Offering Process - The units were offered directly to certain investors under a securities purchase agreement, without the involvement of underwriters or placement agents [4]. - The offering was conducted based on terms negotiated directly between the company and each investor [4]. - The offering was made pursuant to a registration statement declared effective by the SEC on January 2, 2026 [5]. Group 3: Company Overview - STAK Inc. specializes in the research, development, manufacturing, and sale of oilfield-specific production and maintenance equipment [7]. - The company collaborates with specialized vehicle manufacturers to integrate its equipment onto vehicle chassis, producing specialized oilfield vehicles [7]. - STAK aims to help oilfield services companies reduce costs and increase efficiency through integrated equipment and automation solutions [7].

Group 1 - Univest Securities, LLC announced the closing of a registered direct offering of $1.4 million for Globavend Holdings Limited, an emerging e-commerce logistics provider [1] - The offering involved the sale of 889,359 ordinary shares at an effective purchase price of $1.60 per share, resulting in gross proceeds of approximately $1.4 million [2] - The offering was conducted under a registration statement on Form F-3, which was previously filed and declared effective by the U.S. Securities and Exchange Commission [3] Group 2 - Globavend Holdings Limited provides end-to-end logistics solutions primarily for enterprise customers in Hong Kong, Australia, and New Zealand, facilitating B2C transactions [6] - The company offers integrated cross-border logistics services, including parcel drop-off, consolidation, air-freight forwarding, customs clearance, and final delivery [6]

Group 1 - IMUNON, Inc. has entered into a securities purchase agreement for the sale of 1,939,114 shares of common stock and warrants to purchase an equal number of shares, priced at $3.61 each [1][2] - The gross proceeds from the offering are expected to be approximately $7.0 million before deducting fees and expenses [2] - The offering is expected to close on or about December 31, 2025, subject to customary closing conditions [2] Group 2 - Maxim Group LLC is the lead placement agent, with Brookline Capital Markets acting as co-placement agent for the offering [2] - The securities are being offered under a "shelf" registration statement on Form S-3, which was declared effective by the SEC on May 22, 2024 [3] - A prospectus supplement and accompanying prospectus will be filed with the SEC regarding the registered direct offering [3] Group 3 - IMUNON is a clinical-stage biotechnology company focused on developing innovative treatments that utilize the body's natural mechanisms for effective responses to various diseases [5]

Core Viewpoint - LM Funding America, Inc. has announced a registered direct offering to raise approximately $6.5 million through the sale of common stock and pre-funded warrants, along with accompanying warrants for additional shares [1][2]. Group 1: Offering Details - The company will sell 1,822,535 shares of common stock and 7,332,395 pre-funded warrants, with a combined effective offering price of $0.71 per share or pre-funded warrant [1]. - The warrants will have an exercise price of $0.71 and will be exercisable upon stockholder approval, expiring five years from that date [1]. - The company will also reduce the exercise price of existing warrants from $2.95 to $0.87, subject to stockholder approval, and extend their term to five years [1]. Group 2: Financial Proceeds - The gross proceeds from the offering are estimated to be approximately $6.5 million before deducting fees and expenses [2]. - The offering is expected to close on or about December 22, 2025, pending customary closing conditions [2]. Group 3: Regulatory Information - The securities are being offered under a shelf registration statement on Form S-3, effective since November 21, 2024 [3]. - A prospectus supplement related to the offering will be filed with the SEC, and copies will be available through the SEC's website or from the placement agent [3]. Group 4: Company Overview - LM Funding America, Inc. operates as a Bitcoin treasury and mining company, founded in 2008 and based in Tampa, Florida [5]. - The company also provides funding to nonprofit community associations primarily in Florida through a technology-enabled specialty finance business [5].